OpenVSafe by OpenVAERS
Search V-safe

CC2-17887-15146

2 vaccinations 2 coded responses 13 check-ins 2 free-text entries 0 call cases
Sex
Male
Age at first dose
51-55
ZIP prefix
930 / CA
Registered
2021-01-12
Relationship
Self
Race
White
Ethnicity
Not Hispanic or Latino

Timeline

  1. 2020-12-22
    Dose 1 — Pfizer-BioNTech
  2. 2021-01-12
    Registered in v-safe
  3. 2021-01-12
    Dose 2 — Pfizer-BioNTech
  4. 2021-01-12
    Health check-in — day 0, dose 2
    Feeling: Good · None
    Adult check-in
  5. 2021-01-13
    Health check-in — days 1–6 daily, dose 2
    Feeling: Good · Site: Pain · Muscle or body aches, Fatigue or tiredness
    Adult check-in
  6. 2021-01-16
    Health check-in — days 1–6 daily, dose 2
    Feeling: Good · None
    Adult check-in
  7. 2021-01-17
    Health check-in — days 1–6 daily, dose 2
    Feeling: Good · None
    Adult check-in
  8. 2021-01-18
    Health check-in — days 1–6 daily, dose 2
    Feeling: Good · None
    Adult check-in
  9. 2021-01-19
    Health check-in — day 7, dose 2
    Feeling: Good · None
    Adult check-in
  10. 2021-01-26
    Health check-in — day 14, dose 2
    Feeling: Good
    Adult check-in
  11. 2021-02-02
    Health check-in — day 21, dose 2
    Feeling: Good
    Adult check-in
  12. 2021-02-18
    Health check-in — day 35, dose 2
    Feeling: Good
    Adult check-in
  13. 2021-02-25
    Health check-in — day 42, dose 2
    Feeling: Good
    Adult check-in
  14. 2021-04-16
    Health check-in — 3 months, dose 2
    Feeling: Good
    Adult check-in
  15. 2021-07-15
    Survey response — 6 months, dose 2
    MedDRA: Bronchospasm, Cough, Illness, Pyrexia, Tracheobronchitis — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities
    Free text: 2 weeks ago developed trachealbronchitis.Fever with Tmax 104.7 associated with bronchospasm and nonproductive cough. Fever lasted 36 hours, cough 6 days. Daily improvement from onset of illness. No chest pain, SOB. Resolved without sequela.
    MedDRA releases: 2021-09,2024-11 · check-in free text available
  16. 2022-01-14
    Survey response — 12 months, dose 2
    MedDRA: Bronchitis, Nasal congestion, Pyrexia, Rhinorrhoea, SARS-CoV-2 test positive — Feeling: Good
    Free text: Had positive SARS CoV-2 antigen test on 12/31. Symptoms fever (TMAX 102.7) x 2 days followed by bronchitis and Rhinorrea for 5 days. Residual mild nasal congestion x 8 days.
    MedDRA releases: 2024-11 · check-in free text available

Vaccinations

DoseDateManufacturerCo-administered
12020-12-22Pfizer-BioNTech
22021-01-12Pfizer-BioNTech

Free text

Release 9 — 6 months, dose 2

2021-07-15

Symptoms: 2 weeks ago developed trachealbronchitis.Fever with Tmax 104.7 associated with bronchospasm and nonproductive cough. Fever lasted 36 hours, cough 6 days. Daily improvement from onset of illness. No chest pain, SOB. Resolved without sequela.

Release 10 — 12 months, dose 2

2022-01-14

Symptoms: Had positive SARS CoV-2 antigen test on 12/31. Symptoms fever (TMAX 102.7) x 2 days followed by bronchitis and Rhinorrea for 5 days. Residual mild nasal congestion x 8 days.

Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".

MedDRA terms by release

FieldPreferred term2021-092023-042024-11
SDBronchitis · · ✓
SDBronchospasm ✓ · ✓
SDCough ✓ · ✓
SDIllness ✓ · ✓
SDNasal congestion · · ✓
SDPyrexia ✓ · ✓
SDRhinorrhoea · · ✓
SDSARS-CoV-2 test positive · · ✓
SDTracheobronchitis ✓ · ✓

✓ active code · ○ coded but marked inactive · blank = not in that release